Alterity has secured the worldwide exclusive right to patented technology to develop and commercialise therapies that re-sensitise bacteria to antibiotics
Lisa Stockman-Mauriello is dying from ALS, but a pharmaceutical company, Biogen, is trialing a new drug called Torfersen that may buy her a little extra time.